Trillium Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch TRIL and buy or sell other stocks, ETFs, and their options commission-free!

About TRIL

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. 

CEO
Jan Skvarka, PhD, MBA
CEOJan Skvarka, PhD, MBA
Employees
Employees
Headquarters
Mississauga, Ontario
HeadquartersMississauga, Ontario
Founded
2004
Founded2004
Employees
Employees

TRIL Key Statistics

Market cap
1.64B
Market cap1.64B
Price-Earnings ratio
74.87
Price-Earnings ratio74.87
Dividend yield
Dividend yield
Average volume
3.67M
Average volume3.67M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$20.96
52 Week high$20.96
52 Week low
$5.80
52 Week low$5.80

Stock Snapshot

As of today, Trillium Therapeutics(TRIL) shares are valued at $18.44. The company's market cap stands at 1.64B, with a P/E ratio of 74.87.

During the trading day, Trillium Therapeutics(TRIL) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Trillium Therapeutics(TRIL) stock has reached 0, versus its average volume of 3.67M.

The stock's 52-week range extends from a low of $5.80 to a high of $20.96.

The stock's 52-week range extends from a low of $5.80 to a high of $20.96.

People also own

Based on the portfolios of people who own TRIL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.